Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00260481 · ClinicalTrials.gov registry record · Phase 2
Prometa Pharmacotherapy for Methamphetamine Dependence
A Phase 2 study, sponsored by University of California, Los Angeles.
- Completed
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
NCT00260481 is a Phase 2 study that has completed, run by University of California, Los Angeles. The registered enrollment target is 120 participants.
The verdict
NCT00260481, a Phase 2 study, has completed, sponsored by University of California, Los Angeles.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the efficacy of the PROMETA pharmacotherapy compared to placebo for initiating abstinence and for preventing relapse to methamphetamine use in treatment-seeking individuals meeting criteria for methamphetamine abuse. It is hypothesized that individuals assigned to receive the PROMETA pharmacotherapy, compared to placebo, will demonstrate significantly fewer and less intense withdrawal symptoms, more days abstinent from methamphetamine use, and fewer relapses to methamphetamine use as assessed by self-report of drug use verified by urine samples.
Interventions
- DRUG Placebo
- DRUG Prometa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2006-01 |
| Est. Completion | 2008-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00260481
The ClinicalTrials.gov registry entry for NCT00260481 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00260481 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00260481 about?
NCT00260481 is a clinical study titled "Prometa Pharmacotherapy for Methamphetamine Dependence". The purpose of this study is to assess the efficacy of the PROMETA pharmacotherapy compared to placebo for initiating abstinence and for preventing relapse to methamphetamine use in treatment-seeking individuals meeting criteria for methamphetamine abuse. It is hypothesized that individuals assigned...
What is the current status of trial NCT00260481?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2006-01. Estimated completion is 2008-06.
What interventions are being tested in trial NCT00260481?
The interventions under investigation include: Placebo (DRUG), Prometa (DRUG).
Who is sponsoring clinical trial NCT00260481?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.